Therapeutics against cancer and viral infections commonly suffer from several drawbacks including non-selective cytotoxicity, high immunogenicity and low circulation half-lives. The last decade has shown that these therapeutics have embraced conjugation of synthetic polymers and antibodies to therapeutic and cytotoxic payloads.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile